ES2162808T3 - Derivados isoxazol para el tratamiento del sindrome de intestino irritable. - Google Patents

Derivados isoxazol para el tratamiento del sindrome de intestino irritable.

Info

Publication number
ES2162808T3
ES2162808T3 ES93305611T ES93305611T ES2162808T3 ES 2162808 T3 ES2162808 T3 ES 2162808T3 ES 93305611 T ES93305611 T ES 93305611T ES 93305611 T ES93305611 T ES 93305611T ES 2162808 T3 ES2162808 T3 ES 2162808T3
Authority
ES
Spain
Prior art keywords
treatment
intestine syndrome
irritable intestine
derivatives
isoxazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93305611T
Other languages
English (en)
Inventor
Jaswant Singh Gidda
John Mehnert Schaus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2162808T3 publication Critical patent/ES2162808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PROPORCIONA UN METODO PARA EL TRATAMIENTO DEL SINDROME DE INTESTINO IRRITABLE (IBS) USANDO UNA SERIE DE DERIVADOS DE ISOXAZOLA, QUE TIENEN ACTIVIDADES TANTO AGONISTAS 5 HT1A COMO MUSCARINICAS M1, Y FORMULACIONES ADECUADAS DE LAS MISMAS.
ES93305611T 1992-07-17 1993-07-16 Derivados isoxazol para el tratamiento del sindrome de intestino irritable. Expired - Lifetime ES2162808T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US91628192A 1992-07-17 1992-07-17

Publications (1)

Publication Number Publication Date
ES2162808T3 true ES2162808T3 (es) 2002-01-16

Family

ID=25436992

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93305611T Expired - Lifetime ES2162808T3 (es) 1992-07-17 1993-07-16 Derivados isoxazol para el tratamiento del sindrome de intestino irritable.

Country Status (22)

Country Link
US (1) US5434174A (es)
EP (1) EP0579507B1 (es)
JP (1) JPH06166620A (es)
CN (1) CN1049336C (es)
AT (1) ATE206918T1 (es)
AU (1) AU666377B2 (es)
CA (1) CA2100399A1 (es)
CZ (1) CZ284881B6 (es)
DE (1) DE69330926T2 (es)
DK (1) DK0579507T3 (es)
ES (1) ES2162808T3 (es)
HU (1) HUT68727A (es)
IL (1) IL106307A (es)
MX (1) MX9304205A (es)
NO (1) NO304054B1 (es)
PH (1) PH30148A (es)
PL (1) PL172494B1 (es)
PT (1) PT579507E (es)
RU (1) RU2127111C1 (es)
TW (1) TW232653B (es)
UA (1) UA27720C2 (es)
ZA (1) ZA934969B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5962488A (en) * 1998-04-08 1999-10-05 Roberts Laboratories, Inc. Stable pharmaceutical formulations for treating internal bowel syndrome containing isoxazole derivatives
US6362371B1 (en) * 1998-06-08 2002-03-26 Advanced Medicine, Inc. β2- adrenergic receptor agonists
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
US6624388B1 (en) * 2001-01-25 2003-09-23 The Lincoln Electric Company System and method providing distributed welding architecture
RU2178700C1 (ru) * 2001-04-11 2002-01-27 Змызгова Анна Васильевна Способ лечения синдрома раздраженной кишки
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
KR20050111318A (ko) * 2003-01-13 2005-11-24 다이노젠 파마세우티컬스, 인코포레이티드 기능성 장 질환을 치료하는 방법
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
DE602004020069D1 (de) * 2004-09-14 2009-04-30 Fiat Ricerche Vorrichtung und Verfahren zur Qualitätsüberwachung von Industrieprozessen
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
US7684402B2 (en) 2006-05-15 2010-03-23 Faraday Technology Corp. Method and network device for fast look-up in a connection-oriented communication
BR112015015258A2 (pt) 2012-12-24 2017-09-26 Neurogastrx Inc métodos para tratar distúrbios do trato gastrintestinal
WO2015200369A1 (en) 2014-06-24 2015-12-30 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT90366A (pt) * 1988-04-28 1989-11-10 Beecham Group Plc Processo para a producao de compostos glicopeptidicos
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
US5096908A (en) * 1990-05-04 1992-03-17 Eli Lilly And Company Method of inhibiting gastric acid secretion
US5158956A (en) * 1990-05-04 1992-10-27 Eli Lilly And Company Method of inhibiting gastric acid secretion with benzodioxanes
IL114760A (en) * 1991-02-08 1997-11-20 Lilly Co Eli Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto

Also Published As

Publication number Publication date
NO932547D0 (no) 1993-07-13
MX9304205A (es) 1995-01-31
EP0579507A1 (en) 1994-01-19
PT579507E (pt) 2002-02-28
JPH06166620A (ja) 1994-06-14
ATE206918T1 (de) 2001-11-15
PH30148A (en) 1997-01-21
HK1013795A1 (en) 1999-09-10
IL106307A0 (en) 1993-11-15
PL299690A1 (en) 1994-03-21
CZ137193A3 (en) 1994-11-16
HUT68727A (en) 1995-07-28
AU4199393A (en) 1994-01-20
PL172494B1 (pl) 1997-09-30
NO304054B1 (no) 1998-10-19
CN1049336C (zh) 2000-02-16
DE69330926D1 (de) 2001-11-22
EP0579507B1 (en) 2001-10-17
CA2100399A1 (en) 1994-01-18
DK0579507T3 (da) 2001-11-12
AU666377B2 (en) 1996-02-08
HU9302035D0 (en) 1993-10-28
CN1111986A (zh) 1995-11-22
ZA934969B (en) 1995-01-09
IL106307A (en) 1997-06-10
RU2127111C1 (ru) 1999-03-10
UA27720C2 (uk) 2000-10-16
NO932547L (no) 1994-01-18
TW232653B (es) 1994-10-21
DE69330926T2 (de) 2002-04-11
CZ284881B6 (cs) 1999-03-17
US5434174A (en) 1995-07-18

Similar Documents

Publication Publication Date Title
AU666377B2 (en) Isoxazole derivatives for the treatment of irritable bowel syndrome
DK0386997T3 (da) Anvendelse af 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamin-derivater i behandlingen af psykose, inflammation og som immunosuppressive midler
IL98163A0 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides,pharmaceuticals containing these compounds and their use
SE0001330D0 (sv) Novel method of treatment
NO871493L (no) Fremgangsmaate og apparat for undersoekelse av en grunnformasjon som gjennomtrenges av et borehull.
ES2083597T3 (es) Preparacion farmaceutica para el tratamiento del tiempo de coagulacion prolongado.
ES2053748T3 (es) Oxazoles y tiazoles para el tratamiento de la demencia senil.
GB2100601B (en) An aromatase-inhibitor for use in a method of prophylaxis and/or of treatment by therapy of prostatic hyperplasia, and pharmaceutical preparations suitable for such a use.
DK10488D0 (da) Benzen-derivater med antiinflammatorisk virkning og fremgangsmaade til fremstilling deraf
MX9205549A (es) Metodo para el tratamiento de vih.
NO893288L (no) Fremgangsmaate for fremstilling av et nytt antibiotikum, mersacidin, og anvendelse derav som legemiddel.
ES2022192B3 (es) Eteres de oximas sustituidos, su utilizacion como biorreguladores para la reduccion del nivel de etileno endogeno en las plantas.
DK0479093T3 (da) Oligosaccharidderivater og deres anvendelse som lægemidler
ES2181702T3 (es) Derivados de melatonina para su uso en el tratamiento de enfermedad es del sueño.
BR9507521A (pt) Formulação farmacêutica método para o tratemento de infecções bacterianas em seres humanos e animais uso de uma formulação e processo para sua preparação
ATE175960T1 (de) Neue alpha-mannosidase-inhibitoren
PT89742A (pt) Processo de preparacao de 24r-cimnol e de suas composicoes farmaceuticas
NO922635L (no) Ny anvendelse av benzimidazolin-2-okso-1-karboksylsyrederivater
DE3864124D1 (de) Isoxazole mit nootropischer wirkung.
ATE135213T1 (de) Behandlung von tieren
NO922378L (no) Fremgangsmaate for deshydroklorering av 1,1-bis(r-fenyl)-2,2,2-trikloretaner
ES2038634T3 (es) Procedimiento para preparar un nuevo antibiotico macrolido.
MX9203715A (es) Preparciones para el tratamiento del tejido aloinjertado.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 579507

Country of ref document: ES